The US Food and Drug Administration (FDA) has granted approval for Stealth Therapeutics’ Invisiport implantable arm port, intended for use in patients requiring long-term intravenous treatment.

The Invisiport incorporates a patented self-deploying wing that reduces insertion size and improves stability after implantation.

The port provides a less invasive, patient-friendly option to standard chest ports and peripherally inserted central catheters.

Kegonsa Seed Fund and Wisconsin’s premier seed venture capital fund has supported Stealth in FDA submission and commercialisation work.